SI-BONE’s (SIBN) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of SI-BONE (NASDAQ:SIBN) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $25.00 target price on the stock. Cantor Fitzgerald also issued estimates for SI-BONE’s FY2025 earnings at ($0.64) EPS.

Several other research analysts also recently commented on the company. Needham & Company LLC raised their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial raised their price target on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $24.50.

SI-BONE Trading Down 1.9 %

Shares of SIBN opened at $17.81 on Tuesday. The company’s fifty day simple moving average is $16.01 and its 200-day simple moving average is $14.76. The company has a market cap of $746.92 million, a P/E ratio of -19.36 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE has a twelve month low of $11.70 and a twelve month high of $19.16.

SI-BONE (NASDAQ:SIBN) last released its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, analysts expect that SI-BONE will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In related news, insider Anthony J. Recupero sold 3,670 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This represents a 1.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is currently owned by insiders.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC grew its position in SI-BONE by 29.0% during the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after buying an additional 17,410 shares during the period. Millrace Asset Group Inc. purchased a new position in shares of SI-BONE in the third quarter worth about $1,056,000. Champlain Investment Partners LLC grew its stake in SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after acquiring an additional 358,821 shares in the last quarter. Impax Asset Management Group plc lifted its stake in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after purchasing an additional 221,604 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after buying an additional 1,745 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.